GlaxoSmithKline receives EU authorisation for a new therapeutic indication for Tyverb® (lapatinib)

Issued: Wednesday 23 June 2010, London UK GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a variation to the conditional marketing authorisation for Tyverb® (lapatinib) in the European Union for a new therapeutic indication. Tyverb, in combination with an aromatase inhibitor, is indicated for the treatment of post-menopausal women with hormone receptor-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com GlaxoSmithKline Enquiries: UK Media enquiries: Philip Thomson (020) 8047 5502 Claire Brough (020) 8047 5502 Stephen Rea (020) 8047 5502 Alexandra Harrison (020) 8047 5502 Jo Revill (020) 8047 5502 European Analyst/Investor enquiries: David Mawdsley (020) 8047 5564 Sally Ferguson (020) 8047 5543 Gary Davies (020) 8047 5503

The release as fetched from its publisher. gsk.com ↗